Research & Technology The cMet Targeted Agents Platform The foundation technology of EM Imaging revolves around a common platform platform technology with 3 key components: Peptide-based binder that allows specific targeting of disease process. Carrier backbone or pharmacokinetic modulator, coupled to a targeting agent or linker to improve bioavailability/binding affinity and stability. Fluorescent reporter or radionuclide to allow visualisation and/or therapy. EM Imaging has a portfolio of agents addressing a number of unmet medical needs. Agents progressed to date have been found to be safe, tolerable, soluble, specific, sensitive and selective.